Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Monotherapy and Combination Therapy in Adult Participants With Hepatic Impairment

NCT05484206 is registered in ClinicalTrials.gov with Vir Biotechnology, Inc. as lead sponsor.

NCT NCT05484206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05484206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Monotherapy and Combination Therapy in Adult Participants With Hepatic Impairment
Lead sponsor
Vir Biotechnology, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 21, 2022
Completion date
December 9, 2025
Enrollment
88 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, hepatic impairment